Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ariella who wrote (1478)	10/29/1998 8:49:00 PM
From: crysball	Read Replies (2) of 1491

More on Tamoxifen From the description of the patient population at high risk for breast cancer could one also imply the patents will be on long term medication, since the risk factors themselves [genetics/ family history/etc] are not changed by taking Tamoxifen ......hence a very long term market........i.e. if a high risk candidate for breast cancer starts taking Tamoxifen at age 35 she could conceivably continue on the medication for 25 years? Perhaps one of PARS Physician contributors could comment on today's FDA release ?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next